Back to Markets
AMAmylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

AMLXNASDAQ NMS - GLOBAL MARKET
Health CarePharmaceuticals

$14.35

+0.1300 (+0.91%)

As of 05/29/26 EDT · USD

Compare
Low: $4.76Current: $14.35High: $18.61

Key Statistics

Open

$14.19

Day High

$14.37

Day Low

$13.95

Prev. Close

$14.22

VolumeShares traded today.

786.53K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$1.60B

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-9.52

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$18.61

52W LowLowest price over the past 52 weeks.

$4.76

50D MAAverage closing price over the last 50 trading days.

$15.24

200D MAAverage closing price over the last 200 trading days.

$13.68

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

+3.0%

1M

-8.0%

6M

-3.6%

YTD

+25.7%

1Y

+178.6%

About

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

www.amylyx.com/

Company Facts

SectorHealth Care
IndustryPharmaceuticals
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade AMLX

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.